RAGE: a novel biological and genetic marker for vascular disease.
暂无分享,去创建一个
[1] C. Molina,et al. Etiologic Diagnosis of Ischemic Stroke Subtypes With Plasma Biomarkers , 2008, Stroke.
[2] S. Fukumoto,et al. Low Circulating Endogenous Secretory Receptor for AGEs Predicts Cardiovascular Mortality in Patients With End-Stage Renal Disease , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[3] H. Huttunen,et al. Receptor for Advanced Glycation End Products (RAGE)-mediated Neurite Outgrowth and Activation of NF-κB Require the Cytoplasmic Domain of the Receptor but Different Downstream Signaling Pathways* , 1999, The Journal of Biological Chemistry.
[4] C. Falcone,et al. Relationship between the -374T/A RAGE gene polymorphism and angiographic coronary artery disease. , 2004, International journal of molecular medicine.
[5] C. Heizmann,et al. N(epsilon)-carboxymethyllysine-modified proteins are unable to bind to RAGE and activate an inflammatory response. , 2008, Molecular nutrition & food research.
[6] S. Takasawa,et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. , 2003, The Biochemical journal.
[7] P. Gane,et al. The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[8] A. Schmidt,et al. Diabetic vascular disease: it's all the RAGE. , 2005, Antioxidants & redox signaling.
[9] M. Perola,et al. The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. , 2003, Diabetes.
[10] Takafumi Yoshida,et al. Serum Levels of sRAGE, the Soluble Form of Receptor for Advanced Glycation End Products, Are Associated with Inflammatory Markers in Patients with Type 2 Diabetes , 2007, Molecular medicine.
[11] L. Groop,et al. The −374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients , 2006, Diabetologia.
[12] J. Gross,et al. The -374A allele of the receptor for advanced glycation end products gene is associated with a decreased risk of ischemic heart disease in African-Brazilians with type 2 diabetes. , 2005, Molecular genetics and metabolism.
[13] A. Schmidt,et al. Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products* , 1997, The Journal of Biological Chemistry.
[14] T. Kislinger,et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. , 2001, The American journal of pathology.
[15] A. Schmidt,et al. Sp1-binding Elements in the Promoter of RAGE Are Essential for Amphoterin-mediated Gene Expression in Cultured Neuroblastoma Cells* , 1998, The Journal of Biological Chemistry.
[16] A. Alberts,et al. The formins: active scaffolds that remodel the cytoskeleton. , 2003, Trends in cell biology.
[17] Hiroshi Yamamoto,et al. Development of an ELISA for esRAGE and its application to type 1 diabetic patients. , 2006, Diabetes research and clinical practice.
[18] K. Kalantar-Zadeh,et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. , 2003, Kidney international.
[19] E. Ferrannini,et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. , 2006, The Journal of clinical endocrinology and metabolism.
[20] J. Barrett,et al. RAGE polymorphisms and the heritability of insulin resistance: the Leeds Family Study , 2005, Diabetes & vascular disease research.
[21] P. Malherbe,et al. cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. , 1999, Brain research. Molecular brain research.
[22] P. Nawroth,et al. sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes. , 2007, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[23] M. Andrassy,et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. , 2003, The Journal of clinical investigation.
[24] A. Schmidt,et al. Activation of the Receptor for Advanced Glycation End Products Triggers a p21 ras -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress* , 1997, The Journal of Biological Chemistry.
[25] G. Otto,et al. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. , 1995, The American journal of pathology.
[26] P. Guillausseau,et al. Rapid Publication , 1971, Nature.
[27] T. Yoshikawa,et al. Association study of G1704T and G82S polymorphisms of RAGE gene for microalbuminuria in Japanese type 2 diabetic patients. , 2005, Metabolism: clinical and experimental.
[28] P. Massin,et al. Severity of diabetic microvascular complications is associated with a low soluble RAGE level. , 2008, Diabetes & metabolism.
[29] C. Costantini,et al. The −374A allele of the receptor for advanced glycation end products (RAGE) gene promoter is a protective factor against cardiovascular lesions in type 2 diabetes mellitus patients , 2007, Clinical chemistry and laboratory medicine.
[30] H. J. Yoo,et al. Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. , 2009, International journal of cardiology.
[31] E. Sahai,et al. Diaphanous-related formins bridge Rho GTPase and Src tyrosine kinase signaling. , 2000, Molecular cell.
[32] C. Falcone,et al. -374T/A polymorphism of the RAGE gene promoter in relation to severity of coronary atherosclerosis. , 2005, Clinica chimica acta; international journal of clinical chemistry.
[33] HidenoriKoyama,et al. Low Circulating Endogenous Secretory Receptor for AGEs Predicts Cardiovascular Mortality in Patients With End-Stage Renal Disease , 2007 .
[34] Merlin C. Thomas,et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.
[35] T. Hosoya,et al. Relationship Between the −374T/A Receptor of Advanced Glycation End Products Gene Polymorphism and Peritoneal Solute Transport Status at the Initiation of Peritoneal Dialysis , 2007, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[36] E. M. Souza,et al. The Gly82Ser polymorphism of the receptor of advanced glycation end product (RAGE) gene is not associated with type 1 or type 2 diabetes in a Brazilian population. , 2006, Diabetes care.
[37] T. Kislinger,et al. Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases , 2000, Nature.
[38] Hiroshi Yamamoto,et al. De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts. , 2007, Biochimica et biophysica acta.
[39] K. O. Elliston,et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. , 1992, The Journal of biological chemistry.
[40] A. Carter,et al. Identification, classification, and expression of RAGE gene splice variants , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[41] S. Fukumoto,et al. Plasma Level of Endogenous Secretory RAGE Is Associated With Components of the Metabolic Syndrome and Atherosclerosis , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[42] L. Leng,et al. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes , 2006, Diabetologia.
[43] F. Cipollone. 741 The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques , 2003 .
[44] C. Heizmann,et al. S100B and S100A6 Differentially Modulate Cell Survival by Interacting with Distinct RAGE (Receptor for Advanced Glycation End Products) Immunoglobulin Domains* , 2007, Journal of Biological Chemistry.
[45] K. Preissner,et al. The Pattern Recognition Receptor (RAGE) Is a Counterreceptor for Leukocyte Integrins , 2003, The Journal of experimental medicine.
[46] L. Shuqin,et al. -429T/C and -374T/A polymorphisms of RAGE gene promoter are not associated with diabetic retinopathy in Chinese patients with type 2 diabetes. , 2003, Diabetes care.
[47] Y. Zou,et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. , 1993, The American journal of pathology.
[48] T. Quertermous,et al. Molecular Isolation and Characterization of a Soluble Isoform of Activated Leukocyte Cell Adhesion Molecule That Modulates Endothelial Cell Function* , 2004, Journal of Biological Chemistry.
[49] E. Topol,et al. Receptor for AGE (RAGE) Mediates Neointimal Formation in Response to Arterial Injury , 2003, Circulation.
[50] T. Kislinger,et al. RAGE Blockade Stabilizes Established Atherosclerosis in Diabetic Apolipoprotein E–Null Mice , 2002, Circulation.
[51] Hiroshi Yamamoto,et al. The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells* , 2000, The Journal of Biological Chemistry.
[52] J. Traherne,et al. Review Article doi: 10.1111/j.1744-313X.2008.00765.x Blackwell , 2022 .
[53] T. Imaizumi,et al. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein‐1 (MCP‐1) levels in patients with type 2 diabetes , 2008, Diabetes/metabolism research and reviews.
[54] A. D'Angelo,et al. Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Nondiabetic Men , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[55] H. Kaneto,et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. , 2005, Diabetes care.
[56] A. Schmidt,et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.
[57] R. Khalifah,et al. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. , 1999, Biochemical and biophysical research communications.
[58] 田中 伸茂. The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB,and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells , 2001 .
[59] Y. Tomino,et al. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. , 2008, Diabetes research and clinical practice.
[60] F. Santilli,et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. , 2007, Free radical biology & medicine.
[61] G. Norata,et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. , 2009, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[62] L. Groop,et al. Association between LTA, TNF and AGER Polymorphisms and Late Diabetic Complications , 2008, PloS one.
[63] H. Kaneto,et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. , 2009, Atherosclerosis.
[64] C. Heizmann,et al. Structural and functional insights into RAGE activation by multimeric S100B , 2007, The EMBO journal.
[65] H. Kaneto,et al. Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in type 2 diabetic patients. , 2007, Atherosclerosis.
[66] P. Grant,et al. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. , 2001, Diabetes.
[67] P. Gregersen,et al. The RAGE Gly82Ser polymorphism is not associated with cardiovascular disease in the Framingham offspring study. , 2005, Atherosclerosis.
[68] V. Znojil,et al. Haplotype analysis of the RAGE gene: identification of a haplotype marker for diabetic nephropathy in type 2 diabetes mellitus. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[69] A. Schmidt,et al. S100P Stimulates Cell Proliferation and Survival via Receptor for Activated Glycation End Products (RAGE)* , 2004, Journal of Biological Chemistry.
[70] J. Baynes,et al. Oxidation of glycated proteins: age-dependent accumulation of N epsilon-(carboxymethyl)lysine in lens proteins. , 1989, Biochemistry.
[71] R. Ramasamy,et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. , 2008, The Journal of clinical investigation.
[72] I. Fajardy,et al. Human RAGE GLY82SER dimorphism and HLA class II DRB1-DQA1-DQB1 haplotypes in type 1 diabetes. , 1999, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.
[73] P. Majumder,et al. Rage gene promoter polymorphisms and diabetic retinopathy in a clinic-based population from South India , 2007, Eye.
[74] A. Schmidt,et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. , 2006, Atherosclerosis.
[75] K. Herold,et al. The ligand/RAGE axis: Lighting the fuse and igniting vascular stress , 2006, Current atherosclerosis reports.
[76] Yee-Ling Wu,et al. The HLA 8.1 ancestral haplotype is strongly linked to the C allele of -429T>C promoter polymorphism of receptor of the advanced glycation endproduct (RAGE) gene. Haplotype-independent association of the -429C allele with high hemoglobinA1C levels in diabetic patients. , 2007, Molecular immunology.
[77] K. Herold,et al. Blockade of RAGE Suppresses Alloimmune Reactions In Vitro and Delays Allograft Rejection in Murine Heart Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[78] T. Imaizumi,et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. , 2005, Microvascular research.
[79] Paul J Thornalley. Methods for studying the binding of advanced glycated proteins to receptors for advanced glycation endproducts (AGE receptors). , 2002, Methods in molecular biology.
[80] G. Basta. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. , 2008, Atherosclerosis.
[81] X. Chen,et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.
[82] 出石恭久,et al. 肺におけるReceptor for advanced glycation end productsの存在様式の検討 , 2009 .
[83] V. D’Agati,et al. Interaction of the RAGE Cytoplasmic Domain with Diaphanous-1 Is Required for Ligand-stimulated Cellular Migration through Activation of Rac1 and Cdc42* , 2008, Journal of Biological Chemistry.
[84] J. Chen,et al. The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin , 1995, The Journal of Biological Chemistry.
[85] J. Wautier,et al. Mesothelial RAGE activation by AGEs enhances VEGF release and potentiates capillary tube formation. , 2007, Kidney international.
[86] T. Hughes,et al. Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA. , 2004, Diabetes.
[87] R. Muraro,et al. Suppression of Rage as a Basis of Simvastatin-Dependent Plaque Stabilization in Type 2 Diabetes , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[88] I. Lednev,et al. Hexameric Calgranulin C (S100A12) Binds to the Receptor for Advanced Glycated End Products (RAGE) Using Symmetric Hydrophobic Target-binding Patches* , 2006, Journal of Biological Chemistry.
[89] Y. Zou,et al. Receptor for Advanced-Glycation End Products: Key Modulator of Myocardial Ischemic Injury , 2006, Circulation.
[90] A. D'Angelo,et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. , 2005, Archives of neurology.
[91] I. Kubota,et al. Soluble Receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure. , 2008, Journal of cardiac failure.
[92] C. Falcone,et al. The-374T/A Variant of the Rage Gene Promoter is Associated with Clinical Restenosis after Coronary Stent Placement , 2007, International journal of immunopathology and pharmacology.
[93] M. Neurath,et al. RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.
[94] T. Saruta,et al. Relation between development of nephropathy and the p22phox C242T and receptor for advanced glycation end product G1704T gene polymorphisms in type 2 diabetic patients. , 2004, Diabetes care.
[95] J. Mužík,et al. Polymorphisms in the RAGE gene influence susceptibility to diabetes-associated microvascular dermatoses in NIDDM. , 2001, Journal of diabetes and its complications.
[96] B. Peterlin,et al. The - 429 T/C and - 374 T/A gene polymorphisms of the receptor of advanced glycation end products gene are not risk factors for diabetic retinopathy in Caucasians with type 2 diabetes. , 2003, Klinische Monatsblatter fur Augenheilkunde.
[97] J. Ott,et al. Genetic risk factors for diabetic nephropathy on chromosomes 6p and 7q identified by the set-association approach , 2007, Diabetologia.
[98] W. Trojaborg,et al. RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[99] V. D’Agati,et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. , 2003, The American journal of pathology.
[100] P. Grant,et al. Characterization of allelic and nucleotide variation between the RAGE gene on chromosome 6 and a homologous pseudogene sequence to its 5' regulatory region on chromosome 3: implications for polymorphic studies in diabetes. , 2001, Diabetes.
[101] Clustering of Long-Term Complications in Families With Diabetes in the Diabetes Control and Complications Trial , 1997, Diabetes.
[102] A. D'Angelo,et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension , 2005, Journal of hypertension.
[103] P. Saftig,et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane‐bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10) , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[104] F. Santilli,et al. Soluble RAGE in type 2 diabetes: association with oxidative stress. , 2007, Free radical biology & medicine.
[105] I. Meredith,et al. Cellular adhesion molecules and cardiovascular disease. Part I. Their expression and role in atherogenesis , 2003, Internal medicine journal.
[106] M. Crow,et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. , 2001, Diabetes.
[107] T. Misteli,et al. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2010, Nature.
[108] Jerzy K. Kulski,et al. An update of the HLA genomic region, locus information and disease associations: 2004. , 2004, Tissue antigens.
[109] E. Vlková,et al. Polymorphisms 1704G/T, 2184A/G, and 2245G/A in the rage gene are not associated with diabetic retinopathy in NIDDM: pilot study. , 2002, Retina.
[110] E. Topol,et al. Genetic susceptibility to myocardial infarction and coronary artery disease. , 2006, Human molecular genetics.
[111] Jeon-Soo Shin,et al. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. , 2004, Molecular immunology.
[112] T. Yoshikawa,et al. Relation between polymorphisms G1704T and G82S of rage gene and diabetic retinopathy in Japanese type 2 diabetic patients. , 2005, Internal medicine.
[113] V. Tesar,et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[114] P. Ridker,et al. Polymorphisms in the Advanced Glycosylation End Product–Specific Receptor Gene and Risk of Incident Myocardial Infarction or Ischemic Stroke , 2006, Stroke.
[115] V. Tesar,et al. Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[116] L. Liu,et al. RAGE Gly82Ser polymorphism in diabetic microangiopathy. , 1999, Diabetes care.
[117] T. Kislinger,et al. N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.
[118] Shitao Li,et al. Receptor for advanced glycation end products (RAGE) mediates neuronal differentiation and neurite outgrowth , 2008, Journal of neuroscience research.
[119] V. D’Agati,et al. Receptor for Advanced Glycation End Products Mediates Inflammation and Enhanced Expression of Tissue Factor in Vasculature of Diabetic Apolipoprotein E–Null Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[120] P. Rogalla,et al. Tissue-specific expression patterns of the RAGE receptor and its soluble forms--a result of regulated alternative splicing? , 2003, Biochimica et biophysica acta.
[121] Takafumi Yoshida,et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease , 2007, Diabetes/metabolism research and reviews.
[122] T. Sécher. Soluble NCAM , 2008, Neurochemical Research.
[123] C. Falcone,et al. The -374T/A RAGE polymorphism protects against future cardiac events in nondiabetic patients with coronary artery disease. , 2008, Archives of medical research.
[124] I. Fajardy,et al. Polymorphisms of the receptor of advanced glycation endproducts (RAGE) and the development of nephropathy in type 1 diabetic patients. , 2005, Diabetes & metabolism.
[125] S. Fukumoto,et al. Receptor for Advanced Glycation End Products Is Involved in Impaired Angiogenic Response in Diabetes , 2006, Diabetes.
[126] M. Laakso,et al. Gly82Ser polymorphism of the receptor of advanced glycation end product gene is not associated with coronary heart disease in Finnish nondiabetic subjects or in patients with type 2 diabetes. , 2000, Diabetes care.
[127] C. Heizmann,et al. The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. , 2007, Biochemistry.
[128] C. Heizmann,et al. Calcium-regulated intramembrane proteolysis of the RAGE receptor. , 2008, Biochemical and biophysical research communications.
[129] H. Kaneto,et al. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients , 2008, Diabetes & vascular disease research.
[130] J. Luban,et al. Blockade of Late Stages of Autoimmune Diabetes by Inhibition of the Receptor for Advanced Glycation End Products1 , 2004, The Journal of Immunology.
[131] Saeid Ghavami,et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase‐dependent pathway , 2008, Journal of leukocyte biology.
[132] P. Grant,et al. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. , 1998, Diabetes.
[133] P. Gregersen,et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response , 2002, Genes and Immunity.
[134] J. Wautier,et al. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. , 2002, Kidney international.
[135] H. Parving,et al. Polymorphism screening of four genes encoding advanced glycation end-product putative receptors. Association study with nephropathy in type 1 diabetic patients. , 2001, Diabetes.
[136] R. Hoffmann,et al. Structural Basis for Pattern Recognition by the Receptor for Advanced Glycation End Products (RAGE)* , 2008, Journal of Biological Chemistry.
[137] H. Tse,et al. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes , 2007, Diabetologia.
[138] V. D’Agati,et al. The biology of RAGE and its ligands: Uncovering mechanisms at the heart of diabetes and its complications , 2007, Current diabetes reports.
[139] V. D’Agati,et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. , 2000, Journal of the American Society of Nephrology : JASN.